Journal ArticleDOI
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Gary J. Kelloff,John M. Hoffman,Bruce E. Johnson,Howard I. Scher,Barry A. Siegel,Edward Y. Cheng,Bruce D. Cheson,Joyce O'Shaughnessy,Kathryn Z. Guyton,David A. Mankoff,Lalitha K. Shankar,Steven M. Larson,Caroline C. Sigman,Richard L. Schilsky,Daniel C. Sullivan +14 more
Reads0
Chats0
TLDR
Its potential to facilitate drug development in seven oncologic settings (lung, lymphoma, breast, prostate, sarcoma, colorectal, and ovary) is addressed and its potential as a surrogate of clinical benefit is addressed.Abstract:
2-[(18)F]Fluoro-2-deoxyglucose positron emission tomography (FDG-PET) assesses a fundamental property of neoplasia, the Warburg effect. This molecular imaging technique offers a complementary approach to anatomic imaging that is more sensitive and specific in certain cancers. FDG-PET has been widely applied in oncology primarily as a staging and restaging tool that can guide patient care. However, because it accurately detects recurrent or residual disease, FDG-PET also has significant potential for assessing therapy response. In this regard, it can improve patient management by identifying responders early, before tumor size is reduced; nonresponders could discontinue futile therapy. Moreover, a reduction in the FDG-PET signal within days or weeks of initiating therapy (e.g., in lymphoma, non-small cell lung, and esophageal cancer) significantly correlates with prolonged survival and other clinical end points now used in drug approvals. These findings suggest that FDG-PET could facilitate drug development as an early surrogate of clinical benefit. This article reviews the scientific basis of FDG-PET and its development and application as a valuable oncology imaging tool. Its potential to facilitate drug development in seven oncologic settings (lung, lymphoma, breast, prostate, sarcoma, colorectal, and ovary) is addressed. Recommendations include initial validation against approved therapies, retrospective analyses to define the magnitude of change indicative of response, further prospective validation as a surrogate of clinical benefit, and application as a phase II/III trial end point to accelerate evaluation and approval of novel regimens and therapies.read more
Citations
More filters
Journal ArticleDOI
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
TL;DR: Qualitative and quantitative approaches to 18F-FDG PET response assessment have been applied and require a consistent PET methodology to allow quantitative assessments and the proposed PERCIST 1.0 criteria should serve as a starting point for use in clinical trials and in structured quantitative clinical reporting.
Journal ArticleDOI
From Krebs to clinic: glutamine metabolism to cancer therapy.
TL;DR: An updated overview of glutamine metabolism and its involvement in tumorigenesis in vitro and in vivo is provided, and the recent potential applications of basic science discoveries in the clinical setting are explored.
Preoperative staging of non-small-cell lung cancer with positron-emission tomography.
RM Pieterman,Jwg van Putten,JJ Meuzelaar,E. L. Mooyaart,W Vaalburg,Gerard H. Koëter,Fidler,Jan Pruim,Hendricus Groen +8 more
TL;DR: The use of PET to identify the stage of the disease resulted in a different stage from the one determined by standard methods in 62 patients: the stage was lowered in 20 and raised in 42.
Journal ArticleDOI
Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells.
Min Wu,Andy Neilson,Amy L. Swift,Rebecca Moran,James Tamagnine,Diane Parslow,Suzanne Armistead,Kristie Lemire,Jim Orrell,Jay S. Teich,Steve Chomicz,David A. Ferrick +11 more
TL;DR: A bioenergetic phenotype of these two cancer cell lines characterized by increased rate of glycolysis and a linked attenuation in their OXPHOS capacity is demonstrated, providing a mechanistic explanation for the growth advantage and apoptotic resistance of tumor cells.
Journal ArticleDOI
New Technologies for Human Cancer Imaging
TL;DR: The physics and chemistry of cancer imaging is analyzed and the fundamental principles underlying the detection of malignant cells within a background of normal cells are highlighted.
References
More filters
Journal ArticleDOI
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
Thomas J. Lynch,Daphne W. Bell,Raffaella Sordella,Sarada Gurubhagavatula,Ross A. Okimoto,Brian W. Brannigan,Patricia L. Harris,Sara M. Haserlat,Jeffrey G. Supko,Frank G. Haluska,David N. Louis,David C. Christiani,Jeff Settleman,Daniel A. Haber +13 more
TL;DR: A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene which correlate with clinical responsiveness to the tyrosine kinase inhibitor gefitinib, and these mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.
Journal ArticleDOI
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J. Guillermo Paez,Pasi A. Jänne,Pasi A. Jänne,Jeffrey C. Lee,Sean Tracy,Heidi Greulich,Heidi Greulich,Stacey Gabriel,Paula Herman,Frederic J. Kaye,Neal I. Lindeman,Titus J. Boggon,Katsuhiko Naoki,Hidefumini Sasaki,Yoshitaka Fujii,Michael J. Eck,William R. Sellers,William R. Sellers,William R. Sellers,Bruce E. Johnson,Bruce E. Johnson,Matthew Meyerson,Matthew Meyerson +22 more
TL;DR: Results suggest that EGFR mutations may predict sensitivity to gefitinib, and treatment with the EGFR kinase inhibitor gefitsinib causes tumor regression in some patients with NSCLC, more frequently in Japan.
Journal ArticleDOI
Targeting HIF-1 for cancer therapy
TL;DR: Hypoxia-inducible factor 1 (HIF-1) activates the transcription of genes that are involved in crucial aspects of cancer biology, including angiogenesis, cell survival, glucose metabolism and invasion.
Journal ArticleDOI
The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat.
Louis Sokoloff,Martin Reivich,Charles Kennedy,Charles Kennedy,M. H. Des Rosiers,Clifford S. Patlak,Karen D. Pettigrew,O. Sakurada,M. Shinohara +8 more
TL;DR: The method can be applied to most laboratory animals in the conscious state and is based on the use of 2‐deoxy‐D‐[14C]glucose as a tracer for the exchange of glucose between plasma and brain and its phosphorylation by hexokinase in the tissues.
Journal ArticleDOI
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
William Pao,Vincent A. Miller,Maureen F. Zakowski,Jennifer Doherty,Katerina Politi,Inderpal S. Sarkaria,Bhuvanesh Singh,Robert T. Heelan,Valerie W. Rusch,Lucinda Fulton,Elaine R. Mardis,Doris M. Kupfer,Richard K. Wilson,Mark G. Kris,Harold E. Varmus +14 more
TL;DR: Data show that adenocarcinomas from never smokers comprise a distinct subset of lung cancers, frequently containing mutations within the TK domain of EGFR that are associated with gefitinib and erlotinib sensitivity.